申请人:Takeda Pharmaceutical Company Limited
公开号:US20210087186A1
公开(公告)日:2021-03-25
The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I)
wherein each symbol is as described in the specification, or a salt thereof.
本发明提供一种具有降低葡糖鞘脂的作用(例如促进葡糖鞘脂代谢、抑制葡糖鞘脂合成、促进葡糖鞘脂分解等)的化合物,预计可用作预防或治疗溶酶体疾病(例如高雪氏病)、神经退行性疾病(例如帕金森病、路易体痴呆症、多系统萎缩症)等的药剂。本发明涉及一种由式(I)表示的化合物
其中每个符号如说明书中所述,或其盐。